NCT02305589

Brief Summary

This study evaluated the effect of sugammadex on postoperative delirium in elderly patients undergoing hip fracture surgery. Medical records from 235 consecutive patients undergoing hip fracture surgery were retrospectively reviewed and total 61 patients were excluded for age under 60 years, preoperative neurologic problem. Finally total 174 patients aged over 60 years undergoing hip fracture surgery with general anaesthesia using a neuromuscular blocking agent from 2012 to 2014 at a university hospital were analyzed to compare perioperative incidence of postoperative delirium, pulmonary complications, intensive care unit (ICU) admission, and ICU and hospital stay duration and laboratory findings between patients treated with sugammadex (S group) and conventional cholinesterase inhibitors (C group).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 17, 2014

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 2, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

December 16, 2015

Status Verified

December 1, 2015

Enrollment Period

1.7 years

First QC Date

November 17, 2014

Last Update Submit

December 14, 2015

Conditions

Keywords

postoperative deliriumsugammadexcholinesterase inhibitorhip fracture surgery

Outcome Measures

Primary Outcomes (1)

  • Incidence of postoperative delirium

    up to postoperative 7 days

Interventions

Muscle relax reversing agent

Also known as: Bridion

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients undergoing hip surgery under general anaesthesia with neuromuscular blocking agents

You may qualify if:

  • Patients undergoing hip surgery under general anaesthesia with neuromuscular blocking agents

You may not qualify if:

  • age \< 60 years
  • preoperative neurologic or psychological problem including dementia, Parkinson's disease or delirium
  • other concurrent surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Konkuk University Medical Center

Seoul, 143-729, South Korea

RECRUITING

Related Publications (3)

  • Krenk L, Rasmussen LS. Postoperative delirium and postoperative cognitive dysfunction in the elderly - what are the differences? Minerva Anestesiol. 2011 Jul;77(7):742-9.

  • Zywiel MG, Prabhu A, Perruccio AV, Gandhi R. The influence of anesthesia and pain management on cognitive dysfunction after joint arthroplasty: a systematic review. Clin Orthop Relat Res. 2014 May;472(5):1453-66. doi: 10.1007/s11999-013-3363-2.

  • Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology. 2010 Apr;112(4):1013-22. doi: 10.1097/ALN.0b013e3181cded07. No abstract available.

MeSH Terms

Conditions

DeliriumEmergence Delirium

Interventions

Sugammadex

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental DisordersPostoperative ComplicationsPathologic Processes

Intervention Hierarchy (Ancestors)

gamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsPolycyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydrates

Study Officials

  • Seong-Hyop Kim, M.D., Ph.D.

    Konkuk University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Seong-Hyop Kim, M.D., Ph.D.

CONTACT

Chung-Sik Oh, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 17, 2014

First Posted

December 2, 2014

Study Start

September 1, 2014

Primary Completion

May 1, 2016

Study Completion

November 1, 2016

Last Updated

December 16, 2015

Record last verified: 2015-12

Locations